Direct Flow wins FDA nod for U.S. trial; Devicor buys biopsy tech;

@FierceMedDev: Efforts to repeal device tax stall ahead of Memorial Day break. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: PwC says be on the lookout for 'transformational' med tech deals. Report | Follow @VarunSaxena2

@MichaelGFierce: UC Davis team isolates fungus enzyme to cross blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: ICYMI yesterday: Medtronic and Edwards Lifesciences settle the score in ongoing patent feud. Article | Follow @EmilyWFierce

> Direct Flow Medical secured the FDA's blessing to start a U.S. trial of its transcatheter aortic valve system. News

> Boston startup Cocoon Biotech is raising a $750,000 seed round to develop injectable silk designed to treat joint ailments. More

> Cincinnati's Devicor Medical, maker of minimally invasive biopsy devices, has acquired the rights to Biopsy Sciences' HydroMark technology. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Angry $AZN investors may hold the only key to a $PFE deal. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: You ever notice how a statement from Big Pharma often sounds like it came from the Death Star? And they wonder why they have such a bad rep. | Follow @JohnCFierce

@DamianFierce: Takeda's IBD drug vedolizumab wins FDA approval, will sell as Entyvio. Report | Follow @DamianFierce

@EmilyMFierce: Animal model that mimics hep B, C in humans could spur new treatments. FierceBiotech Research story | Follow @EmilyMFierce

> Swelling ranks of AstraZeneca's dissident shareholders press for a Pfizer deal. Story

> AstraZeneca partner Ardelyx pitches $69M IPO. Item

> Shire heads to the FDA with its dry eye drug despite a so-so PhIII. Article

> Gene therapy upstart bags a $22M A round for neurodegenerative work. News

Pharma News

@FiercePharma: Top-read on FP Tues: How did AstraZeneca make the Pfizer bid a Harry vs. Voldemort story? Article | Follow @FiercePharma

@TracyStaton: Some $AZN investors are balking at the board's $PFE snub. Others are practically high-fiving Chairman Johannson. More from Reuters | Follow @TracyStaton

@EricPFierce: warning letter ravages Sun Pharma's data deletion methods at plant in Gujarat. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Should FDA allow drug ads to include price comparisons? A planned study aims to find out. FiercePharmaMarketing story | Follow @CarlyHFierce

> Need a job? J&J, Novartis and Biogen Idec are pharma's favorite employers. Article

> Emerging market playbook: Egypt's Amoun Pharma puts itself on the block. More

> Who gets the likes when it comes to job hunting? Think J&J, Novartis and Biogen Idec. Story

Drug Delivery News

> Stem cells loaded with herpesvirus attack glioblastoma brain tumors in mice. Story

> Phosphagenics' animal health topical patch shows promise. Story

> Smallest, fastest nanomotor moves drugs and releases them on demand. More

> New data boost Insmed's inhaled liposomal delivery mechanism for lung infections. Article

> Reckitt Benckiser to develop nasal spray for emergency overdose of opioids. Report

Diagnostics News

> KineMed, CHDI extend their Huntington's biomarker development deal. News

> Blood Dx shows promise helping women to predict premature labor. Report

> German researchers tie CTC presence to breast cancer survival odds. More

> Water Street bets on German specialty Dx outfit. Article

> U.K.'s Enigma Diagnostics jumps into China with disease pathogen testing. Story

Pharma Marketing News

> Top payer group shoots down Gilead's hep C drug Sovaldi on price. Item

> Novo preps for FDA panel hearing on lucrative obesity use for liraglutide. Story

> FDA weighs the free-speech case for off-label marketing. Report

> Allergan's pipeline in a drug, Botox could keep new marketing twists coming. Article

Suggested Articles

J.D. Power aims to set the benchmarks in telehealth satisfaction with a new study due this November.

Atomwise plans to screen up to 10 billion virtual compounds for therapies against childhood cancer in collaboration with chemical supplier Enamine.

The Chan Zuckerberg Initiative set aside $68 million for over three dozen projects in an effort to map out every type of cell in the body.